Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.
CDNA - CareDx, Inc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$58.75
DETAILS
HIGH:
$65.00
LOW:
$46.00
MEDIAN:
$62.00
CONSENSUS:
$58.75
UPSIDE:
17.76%
Stock News
Are Medical Stocks Lagging CareDx (CDNA) This Year?
Here is how CareDx (CDNA) and Concentra Group (CON) have performed compared to their sector so far this year.
Canada Pension Plan Investment Board Takes Position in CareDx, Inc. $CDNA
Canada Pension Plan Investment Board purchased a new position in shares of CareDx, Inc. (NASDAQ: CDNA) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 52,800 shares of the company's stock, valued at approximately $1,505,000. Canada Pension Plan Investment Board owned 0.10%
CareDx (CDNA) is a Great Momentum Stock: Should You Buy?
Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Bamco Inc. NY Makes New $55.21 Million Investment in CareDx, Inc. $CDNA
Bamco Inc. NY bought a new stake in CareDx, Inc. (NASDAQ: CDNA) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,937,326 shares of the company's stock, valued at approximately $55,214,000. Bamco Inc. NY owned approximately 3.75% of CareDx as of
Zacks Industry Outlook CareDx, BrightSpring and PACS
CareDx, BrightSpring and PACS have been highlighted in this Industry Outlook article.
3 Medical Service Stocks Resilient Amid Persistent Workforce Shortage
CareDx, BrightSpring and PACS Group are positioned for growth as digital health expands and workforce shortages reshape medical services.
Ron Baron Trims CareDx Inc (CDNA) Stake -- Shares Trade 86% Above GF Value
On June 30, 2026, Ron Baron (Trades, Portfolio) executed a significant reduction in the firm's position in CareDx Inc (NASDAQ: CDNA), selling 1,399,083 shares at
5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns
Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On August 5, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an aggregate of 97,090 shares of common stock. With respect to 34 of the new employees, an aggregate of 93,090 of the RSUs will vest o.
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 30, 2026, CareDx granted to James McNally, the Company's newly appointed Executive Advisor, certain stock awards as an inducement material to Mr. McNally's employment with CareDx. CareDx granted 15,822 shares of common stock restricted stock units (RSUs) to Mr. McNally. The RSU awards were made pursua.
Why CareDx Stock Jumped Today
CareDx is helping to improve outcomes for transplant patients. The health monitor's non-invasive tests are in high demand.
CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript
CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript
CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates
CareDx (CDNA) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.1 per share a year ago.
CareDx Q2 Earnings Call Highlights
CareDx NASDAQ: CDNA reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began integrating the recently acquired NavDx specialty oncology platform.
CareDx Announces Second Quarter 2026 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Revenue of $132 million, an increase of 52% year-over-year Testing Services revenue of $100 million, an increase of 61% year-over-year, and Testing Services volume of approximately 58,000, an increase of 17% year-o.
CareDx (CDNA) Earnings Expected to Grow: Should You Buy?
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amova Asset Management Americas Inc. Increases Position in CareDx, Inc. $CDNA
Amova Asset Management Americas Inc. raised its holdings in shares of CareDx, Inc. (NASDAQ: CDNA) by 2.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,475,126 shares of the company's stock after purchasing an additional 28,510 shares during the period. Amova Asset
CareDx's Growth Prospects With Naveris Keep Me Bullish
CareDx has a transplant-testing franchise that taps into recurring surveillance demand and has deeper integration into transplant centers. I also think CDNA's AlloHeme gives them longer-term optionality in post-cell-therapy monitoring. More recently, CDNA sold Lab Products and purchased Naveris. These major strategic M&A deals mean CDNA now has a potential growth engine in oncology.
CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last?
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Price Targets
CareDx initiated with a Buy at Canaccord
$65.00
(was $48.97)
Canaccord Genuity
CareDx price target raised to $60 from $45 at BTIG
$60.00
(was $45.50)
BTIG
CareDx upgraded to Buy from Hold at Craig-Hallum
$64.00
(was $43.71)
Craig-Hallum
H.C. Wainwright Reiterates Neutral Rating on CareDx, Inc (CDNA)
$46.00
(was $38.10)
Yi Chen
·
H.C. Wainwright
CareDx price target raised to $45 from $28 at BTIG
$45.00
(was $38.59)
BTIG
Craig-Hallum ups CareDx price target after 'quite favorable' Medicare LCD
$35.00
(was $36.91)
Craig-Hallum
CareDx price target raised to $28 from $26 at BTIG
$28.00
(was $21.91)
BTIG
CareDx, Inc (CDNA) PT Raised to $26 at BTIG
$26.00
(was $18.46)
Sung Ji Nam
·
BTIG
CareDx downgraded to Hold from Buy at Craig-Hallum
$26.00
(was $19.81)
Craig-Hallum
CareDx price target raised to $18 from $14 at Wells Fargo
$18.00
(was $20.57)
Brandon Couillard
·
Wells Fargo
CareDx price target lowered to $25 from $26 at H.C. Wainwright
$25.00
(was $21.13)
H.C. Wainwright
CareDx, Inc (CDNA) PT Lowered to $35 at BTIG
$35.00
(was $22.90)
Sung Ji Nam
·
BTIG
CareDx upgraded to Buy from Neutral at BTIG
$40.00
(was $33.00)
Mark Massaro
·
BTIG
CareDx price target raised to $40 from $32 at Craig-Hallum
$40.00
(was $32.98)
Bill Bonello
·
Craig-Hallum
CareDx price target raised to $32 from $22 at Craig-Hallum
$32.00
(was $19.99)
Bill Bonello
·
Craig-Hallum
Stephens Reiterates Overweight Rating on CareDx, Inc (CDNA)
$15.00
(was $8.29)
Mason Carrico
·
Stephens
Goldman Sachs Maintains Buy on CareDx, Lowers Price Target to $29
$29.00
(was $16.26)
Goldman Sachs
Stephens & Co. Initiates Coverage On CareDx with Overweight Rating, Announces Price Target of $50
$50.00
(was $31.72)
Stephens